The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients

SIMPLE SUMMARY: Ovarian cancer (OC) is the most lethal gynecological malignancy with a five-year survival rate of 47%, followed by cervical cancer (66%), and uterine cancer (81%). Despite the success of immunotherapies based on the programmed cell death pathway (PD-1/PD-L1) in other solid cancers, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pawłowska, Anna, Skiba, Wiktoria, Suszczyk, Dorota, Kuryło, Weronika, Jakubowicz-Gil, Joanna, Paduch, Roman, Wertel, Iwona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740841/
https://www.ncbi.nlm.nih.gov/pubmed/36497240
http://dx.doi.org/10.3390/cancers14235757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740841/
https://www.ncbi.nlm.nih.gov/pubmed/36497240
http://dx.doi.org/10.3390/cancers14235757

Ejemplares similares